Pemetinib’s latest selling price and medical insurance reimbursement details in 2024

Pemigatinib (Pemigatinib), trade name PEMAZYRE, has attracted much attention in recent years as a targeted therapy drug for patients with cholangiocarcinoma and other tumors with specific gene mutations. In 2024, the latest selling price and medical insurance reimbursement status of pemetinib have become the focus of concern for many patients and medical workers.

In terms of selling price, the price of pemetinib in the Chinese market is relatively high. A box of pemetinib tablets (Dabotan/PEMAZYRE) sells for approximately tens of thousands of yuan, which is undoubtedly a considerable expense for many patient families. However, it’s worth noting that there are some more affordable options on the market. For example, Lucius Pharmaceuticals in Laos sells a generic version of pemetinib, which is priced at about 800 to 900 yuan. This price greatly reduces the financial burden of patients.

In terms of medical insurance reimbursement, pemetinib has not yet been included in my country's medical insurance catalog, which means that patients need to bear all costs when purchasing the drug. However, with the continuous adjustment and improvement of medical insurance policies, pemetinib may be included in the medical insurance catalog in the future, thus reducing the financial pressure on patients. For patients who require long-term treatment with pemetinib, the high drug cost is undoubtedly a heavy burden. Therefore, when choosing purchasing channels, patients should fully understand the prices of various versions of pemetinib in order to make the most economical and reasonable choice. At the same time, patients can consult doctors or medical insurance institutions to learn about the latest medical insurance policies and reimbursement status in order to obtain relevant support in a timely manner.

In general, as a highly effective targeted therapy drug, pemetinib’s price and medical insurance reimbursement are crucial to patients. Although pemetinib is not currently included in the medical insurance list, there are some affordable versions on the market that provide patients with more choices.